Pharmacology: Pharmacodynamics: Mechanism of action: Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following attachment to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death. This broad spectrum cephalosporin is active against many important Gram-negative and Gram-positive bacterial pathogens
in vitro. Avibactam is a non β-lactam, β-lactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. It inhibits both Ambler class A and class C β-lactamases, including extended-spectrum β-lactamases (ESBLs), KPC carbapenemases, and AmpC enzymes. Avibactam also inhibits the class D carbapenemase OXA-48, which does not significantly hydrolyze ceftazidime. Avibactam has no clinically relevant
in vitro antibacterial activity. Avibactam did not induce transcription of bla
AmpC in
Enterobacter cloacae, Citrobacter freundii or
Pseudomonas aeruginosa in vitro at concentrations used to treat patients.
Mechanism of resistance: Ceftazidime-avibactam is not active against metallo-β-lactamase-producing bacteria. Bacterial resistance mechanisms that could potentially affect ceftazidime-avibactam include mutant or acquired PBPs, decreased outer membrane permeability to either compound, active efflux of either compound, mutated or acquired β-lactamase enzymes insensitive to avibactam and able to hydrolyze ceftazidime.
Cross-resistance: An absence of cross-resistance between ceftazidime-avibactam and fluoroquinolones or aminoglycosides has been demonstrated
in vitro using molecularly-characterized clinical isolates. Some isolates resistant to ceftazidime (and other cephalosporins) or to carbapenems are susceptible to ceftazidime-avibactam. There is cross-resistance with β-lactam antibacterial agents, including carbapenems, when the mechanism is production of metallo-β-lactamases, such as VIM-2.
Interaction with other antimicrobial agents: In vitro interaction tests with ceftazidime-avibactam show ceftazidime-avibactam has little potential to antagonize or be antagonized by other antibiotics of various classes (e.g. metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin, tigecycline).
Susceptibility testing: The prevalence of acquired resistance may vary geographically and with time for selected species. Local information on resistance is desirable, particularly when treating severe infections.
The susceptibility to ceftazidime-avibactam of a given clinical isolate should be determined by standard methods. Interpretations of test results should be made in accordance with local infectious diseases and clinical microbiology guidelines.
Pharmacokinetic/pharmacodynamic relationship: The antimicrobial activity of ceftazidime-avibactam against specific pathogens has been shown to best correlate with the percent time of free-drug concentration above the ceftazidime-avibactam minimum inhibitory concentration over the dose interval (%fT > MIC of ceftazidime-avibactam) for ceftazidime, and the percent time of the free drug concentration above a threshold concentration over the dose interval (% fT>CT) for avibactam.
Clinical efficacy against specific pathogens: Efficacy has been demonstrated in clinical studies against the pathogens, listed under each indication, that were susceptible to ceftazidime-avibactam
in vitro.
Complicated intra-abdominal infections: Gram-negative micro-organisms:
Citrobacter freundii;
Enterobacter cloacae;
Escherichia coli;
Klebsiella oxytoca;
Klebsiella pneumoniae;
Pseudomonas aeruginosa.
Complicated urinary-tract infections: Gram-negative micro-organisms:
Escherichia coli;
Klebsiella pneumoniae;
Proteus mirabilis;
Enterobacter cloacae;
Pseudomonas aeruginosa.
Hospital-acquired pneumonia including ventilator-associated pneumonia: Gram-negative micro-organisms:
Enterobacter cloacae;
Escherichia coli;
Klebsiella pneumoniae;
Proteus mirabilis;
Serratia marcescens;
Pseudomonas aeruginosa.
Clinical efficacy has not been established against the following pathogens that are relevant to the approved indications although
in vitro studies suggest that they would be susceptible to ceftazidime-avibactam in the absence of acquired mechanisms of resistance.
Gram-negative micro-organisms:
Citrobacter koseri;
Enterobacter aerogenes;
Morganella morganii;
Proteus vulgaris;
Providencia rettgeri.
Ceftazidime-avibactam is active
in vitro against
Streptococcus pyogenes and
Streptococcus agalactiae, but not generally active against other clinically-important Gram-positive bacteria including methicillin-resistant
Staphylococcus aureus (MRSA).
Clinical efficacy and safety: Complicated intra-abdominal infections: A total of 1058 adults with complicated intra-abdominal infections (defined as infections that require surgical intervention and extend beyond the hollow viscus into the intraperitoneal space) were randomized and received treatment in two identical randomized, multi-centre, multinational, double-blind studies (RECLAIM 1 and RECLAIM 2) comparing Ceftazidime-avibactam (2 g of ceftazidime and 500 mg of avibactam) administered intravenously over 120 minutes every 8 hours plus metronidazole (500 mg) to meropenem (1000 mg) administered intravenously over 30 minutes. Treatment duration was 5 to 14 days. The modified intent-to-treat (MITT) population included all patients who met the disease definition of cIAI and received at least 1 dose of the study drug. The clinically evaluable (CE) population included patients who had an appropriate diagnosis of cIAI and excluded patients with a bacterial species typically not expected to respond to both study drugs (i.e.,
Acinetobacter baumannii or
Stenotrophomonas spp) and/or who had an important protocol deviation impacting the assessment of efficacy.
The primary efficacy endpoint was the clinical response at the Test of Cure (TOC) visit in the co-primary populations of the CE and MITT patients in Table 1 as follows.
Click on icon to see table/diagram/image
Clinical cure rates at TOC by pathogen in the microbiologically Modified Intent to Treat (mMITT) population for Gram-negative aerobes are shown in Table 2 as follows.
Click on icon to see table/diagram/image
A further 432 adults with complicated intra-abdominal infections were randomized and received treatment in a multi-centre, double-blind study (RECLAIM 3) conducted in 3 Asian countries (China, Republic of Korea and Vietnam). The patient population and key aspects of the study design were identical to RECLAIM apart from the primary efficacy endpoint of clinical response at the TOC visit being solely in the CE population (see Table 3 as follows).
Click on icon to see table/diagram/image
Clinical cure rates at TOC by pathogen in the microbiologically modified Intent to Treat (mMITT) population for Gram-negative aerobes are shown in Table 4 as follows.
Click on icon to see table/diagram/image
Complicated urinary tract infections: A total of 1020 adults with documented complicated urinary tract infection (cUTI) (737 with acute pyelonephritis and 283 with cUTI without acute pyelonephritis) were randomized and received treatment in a phase III multicentre, double-blind, comparative study. Treatment was with either Ceftazidime-avibactam (2 g/500 mg) IV over 120 mins every 8 hours or doripenem 500 mg IV over 60 mins every 8 hours. There was an optional switch to oral therapy for patients who had clinical improvement as defined in the study protocol after a minimum of 5 days IV treatment. Total duration of antibiotic therapy (IV plus oral) was 10 days (optionally up to 14 if bacteremic). The mMITT population included all patients with a confirmed cUTI diagnosis, received at least 1 dose of study treatment and had a study-qualifying pre-treatment urine culture containing 105 CFU/mL of a Gram-negative pathogen and no more than 2 species of microorganisms. Any patient with a Gram-positive pathogen, or a bacterial species not expected to respond to both study drugs was excluded.
The primary efficacy endpoint was per-patient microbiological response at the TOC visit in the mMITT analysis set. (See Table 5.)
Click on icon to see table/diagram/image
Favourable microbiological response rates at TOC by pathogen in the mMITT population are shown in Table 6 as follows.
Click on icon to see table/diagram/image
Hospital-acquired pneumonia: A total of 808 adults with nosocomial pneumonia (35% with VAP) were randomized and received treatment in a phase III double-blind, comparative study of Ceftazidime-avibactam (2 g/500 mg) IV over 120 mins every 8 hours or meropenem 1g IV over 30 mins every 8 hours. Treatment duration was 7 to 14 days. The clinically modified intent to treat (cMITT) population included patients who met the minimum disease criteria, received at least 1 dose of study treatment and who had properly obtained baseline respiratory or blood cultures demonstrating Gram-negative pathogens excluding patients with monomicrobial Gram-negative infections with species not expected to respond to both study drugs (e.g., Acinetobacter species or Stenotrophomonas species). The cMITT also included patients in whom no etiologic pathogens were identified from respiratory or blood cultures at baseline. The CE at TOC analyses set was the clinically evaluable subset of the cMITT.
The primary efficacy endpoint was the clinical response at the TOC visit in the co-primary populations of the cMITT and CE at TOC. See Table 7 as follows.
Click on icon to see table/diagram/image
All-cause mortality rates at Day 28 (cMITT) was 8.4% (30/356) and 7.3% (27/370) ceftazidime-avibactam and meropenem treated patients, respectively.
Clinical cure rate and favourable microbiological response rate at TOC by pathogen in mMITT for Gram-negative aerobes are shown in Tables 8 and 9.
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Pharmacokinetics: Distribution: The human protein binding of both ceftazidime and avibactam is low, approximately 10% and 8%, respectively. The steady-state volumes of distribution of ceftazidime and avibactam were comparable, about 22 L and 18 L, respectively in healthy adults following multiple doses of 2 g/500 mg ceftazidime-avibactam infused over 2 hours every 8 hours. Pharmacokinetic parameters of ceftazidime and avibactam following single and multiple dose administration of Ceftazidime (as pentahydrate)/Avibactam (as sodium) (Zavicefta) were similar to those determined when ceftazidime or avibactam were administered alone. Both ceftazidime and avibactam penetrate into human bronchial epithelial lining fluid (ELF) to the same extent with concentrations around 30% that of plasma, and a similar concentration time profile between ELF and plasma.
Ceftazidime and avibactam plasma exposure were comparable across patients with different indications, cIAI, cUTI and NP.
Penetration of ceftazidime into the intact blood-brain barrier is poor, resulting in low levels of ceftazidime in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/L or more are achieved in the CSF when the meninges are inflamed. Avibactam penetration of the blood brain barrier has not been studied clinically, however, in rabbits with inflamed meninges, CSF exposures of ceftazidime and avibactam were 43% and 38% of plasma AUC, respectively. For ceftazidime, concentrations in excess of the MIC of ceftazidime-avibactam for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Ceftazidime crosses the placenta readily, and is excreted in the breast milk. Avibactam penetrates into the subcutaneous tissue at the site of skin infections, with tissue concentrations approximately equal to free drug concentrations in plasma.
Biotransformation: Ceftazidime is not metabolized. No metabolism of avibactam was observed in human liver preparations (microsomes and hepatocytes). Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [
14C]-avibactam.
Elimination: The terminal half-life (t½) of both ceftazidime and avibactam is about 2 h after IV administration. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80-90% of the dose is recovered in the urine within 24 h. Avibactam is excreted unchanged into the urine with a renal clearance of approximately 158 ml/min, suggesting active tubular secretion in addition to glomerular filtration; approximately 97% of the dose is recovered in the urine, 95% within 12 h. Less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into feces.
Linearity/non-linearity: The pharmacokinetics of both ceftazidime and avibactam are approximately linear across the dose range studied (50 mg to 2 g) for a single IV administration. No appreciable accumulation of ceftazidime or avibactam was observed following multiple IV infusions of 2 g/500 mg of ceftazidime-avibactam administered every 8 hours for up to 11 days in healthy adults with normal renal function.
Special populations: Patients with renal impairment: Elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment, and end stage renal disease including patients undergoing hemodialysis; the dose should be reduced in patients with CrCl ≤50 ml/min) (see Dosage & Administration).
Patients with hepatic impairment: Mild to moderate hepatic impairment had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g IV every 8 hours for 5 days, provided renal function was not impaired. The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established. The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.
As ceftazidime and avibactam do not appear to undergo significant hepatic metabolism, the systemic clearance of either drug is not expected to be significantly altered by hepatic impairment. Therefore, no dosage adjustment of ceftazidime-avibactam is recommended for patients with hepatic impairment (see Dosage & Administration).
Elderly patients: The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life ranged from 3.5 to 4 hours following single or 7 days repeated every 12 hours dosing of 2 g IV bolus injections in elderly patients 80 years or older.
Following single dose IV administration of 500 mg avibactam as a 30-minute IV infusion, the elderly had a slower terminal half-life of avibactam, which may be attributed to age related decrease in renal clearance. Dosage adjustment for ceftazidime-avibactam is not required in elderly subjects (≥ 65 years of age) with CrCl > 50 ml/min.
Pediatric patients: The safety and efficacy of Ceftazidime (as pentahydrate)/Avibactam (as sodium) (Zavicefta) in pediatric patients (< 18 years of age) have not been established.
Gender: The pharmacokinetics of ceftazidime-avibactam was similar between males and females. No dose adjustment is required based on sex.
Race: Based on a population pharmacokinetic analysis, no dose adjustment of ceftazidime-avibactam is required based on race.
Toxicology: Preclinical Safety Data: Genetic toxicology: For ceftazidime a mouse Micronucleus test and an Ames test were both negative for mutagenic effects. Carcinogenicity studies have not been conducted. In genotoxicity assays with avibactam, there was no induction of gene mutation in the
in vitro bacterial reverse mutation tests, nor were there any indications of genotoxicity in an
in vitro unscheduled DNA synthesis test in rat liver cells or an
in vitro micronucleus test in mouse lymphoma cells. In cultured human lymphocytes, statistically significant increases in chromosomal aberrations were observed under a single treatment condition (44 h harvest time, -S9). As these findings were not replicated in an independent study, the results are considered to be of limited biological relevance. When administered up to the limit dose of 2 g/kg IV, avibactam was negative in a rat
in vivo micronucleus assay. Carcinogenicity studies have not been conducted. No genetic toxicology studies have been conducted on ceftazidime-avibactam.
Reproductive toxicology: Reproduction studies have been performed with ceftazidime in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus. In pregnant rabbits at exposures of avibactam approximately 8 fold higher than those observed in humans at 0.5 g three times daily there was a significant effect on maternal food consumption and a slight effect on fetal weight and slight retardation of ossification of a few bones in the fetus. In the rat, no adverse effects were observed on embryofetal development or fertility. Following administration of avibactam throughout pregnancy and lactation in the rat, there was no effect on pup survival, growth or development, however there was an increase in incidence of dilation of the renal pelvis and ureters in less than 10% of the rat pups at maternal exposures greater than or equal to approximately 1.5 times human therapeutic exposures. No reproductive toxicology studies have been conducted on ceftazidime-avibactam.